A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №2 2025 год

more

A.I. Burnasyan  FMBC clinical bulletin. 2024 № 1

Yu.S. Rusyaykina, A.A. Zavialov, A.I. Tyryshkin, S.E. Varlamova

Taking into Account the Comorbidity Index when Performing Anti-Tumor Drug Therapy in Elderly and Senile Patients with Colorectal Cancer (Literature Review)

International Office, State Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russiа

Contact person: RusyaykinaYulia Sergeevna: rysou1@mail.ru

Abstract
The problem of treating elderly patients is one of the most pressing in modern clinical medicine.
Colorectal cancer is one of the main causes of mortality from malignant neoplasms in Russia and other developed countries. At the same time, the incidence of tumors of the colon and rectum steadily increases with age. Before starting treatment for elderly patients, it is necessary to carefully weigh the potential risks and the possibility of achieving positive results of antitumor therapy.
Objective: To summarize the literature on the use of a comprehensive geriatric assessment, including the Cancer and Aging Research Group (CARG) toxicity assessment, to predict the risk of adverse events during anticancer drug treatment in elderly patients diagnosed with colorectal cancer.
Materials and methods: The search for scientific sources was carried out in PubMed / Medline / UpToDate using the following keywords: “malignant tumors”, “metastatic colorectal cancer”, “senile age”, “antitumor drug therapy”. The time horizon covered 2016–2023. Using a time filter, the most relevant and innovative research papers on the issues of chemotherapy treatment of elderly and senile patients were selected.
Results: Most current evidence demonstrates the importance of performing a comprehensive geriatric assessment (CGA), Cancer and Aging Research Group (CARG) toxicity assessment in elderly and geriatric patients. Information obtained from geriatric assessment should be used to predict and manage treatment toxicity. And also for assessing and predicting overall survival.
Activities based on CGA can reduce the toxicity of chemotherapy, improve the quality of life of patients, and increase compliance with medical recommendations. Undoubtedly, a comprehensive geriatric assessment (CGA) can help achieve the necessary balance between the potential effectiveness and adverse events of chemotherapy.
The choice of treatment tactics for an elderly and senile cancer patient should be based on the patient’s functional status (PS), general somatic status according to the ECOG scale, and the risk of toxicity according to the CARG scale.
In the presence of colorectal cancer, patients with good functional status who need antitumor systemic effects can be prescribed polychemotherapy with FOLFOX, XELOX, FOLFIRI doublets with the addition of targeted drugs: bevacizumab or cetuximab (depending on the results of gene profiling of the tumor).
Patients who are not candidates for polychemotherapy in standard doses, who have a general somatic status on the ECOG scale of 1-2 and an average risk of developing toxicity of grade 3 on the CARG scale, can undergo PCT with FOLFOX, XELOX, FOLFIRI doublets with a reduction in the starting dose by 20%, or monochemotherapy with antimetabolites: capecitabine, 5-fluorouracil; topoisomerase I inhibitor irinotecan.
Patients with poor functional status, general somatic status on the ECOG scale 3-4, and a high risk of developing toxicity on the CARG scale are not candidates for systemic combination chemotherapy. Particular attention should be paid to maintenance therapy in this subgroup of patients. However, if the decrease in PS level is directly related to malignancy and PS ≥2, the possibility of monochemotherapy by infusion of a combination of 5-fluorouracil and leucovorin FU/LV can be evaluated.

Keywords: malignant tumors, metastatic colorectal cancer, senile age, antitumor drug therapy

For citation: RusyaykinaYuS, Zavialov AA, Tyryshkin AI, Varlamova SE. Taking into Account the Comorbidity Index when Performing Anti-Tumor Drug Therapy in Elderly and Senile Patients with Colorectal Cancer (Literature Review). A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2023.4:52-60. (In Russian) DOI: 10.33266/2782-6430-2024-1-52-60

 

REFERENCES

  1. Starostin R.A., Gataulin B.I., Valitov B.R., Gataulin I.G. Colorectal Cancer: Epidemiology and Risk Factors. Povolzhskiy Onkologicheskiy Vestnik = Oncology Bulletin of the Volga Region. 2021;12;4:52-59 (In Russ.).
  2. Kotovskaya Ju.V., Tkacheva O.N. Frailty and Arterial Hypertension: Clinical Practice Issues. Arterialnaya Gipertenziya = Arterial Hypertension. 2023;29;3:246-252 (In Russ.).
  3. Manukyan M.Sh., Bazin I.S., Tryakin A.A. Chemotherapy for Advanced Pancreatic Cancer in Older Patients (Literature Review). Tazovaya Khirurgiya i Onkologiya = Pelvic Surgery and Oncology. 2022;12;3:51-55 (In Russ.).
  4. Gromova E.G. Renal Failure in Patients with Hematological Malignancies (Literature Review). Onkogematologiya = Oncohematology. 2021;16;4:59-63 (In Russ.).
  5. Burnasheva E.V., Shatokhin Yu.V., Snezhko I.V., Matsuga A.A. Kidney Injury in Cancer Therapy. Nefrologiya = Nefrology. 2018;22;5:17–24 (In Russ.).
  6. Grivtsova L.Yu., Larionova V.B., Falaleyeva N.A. Immunocorrective Treatment Use in the Prevention of Hematological and Infectious Complications of Chemotherapy in Cancer Patients. Onkogematologiya = Oncohematology. 2021;16;4:23-30 (In Russ.).
  7. Volkova M.I., Gridneva Ya.V., Olshanskaya A.S. Cabazitaxel in the Treatment of Castration-Resistant Cancer: Hitting the Balance of Efficacy and Safety? Meditsinskiy Sovet = Medical Council. 2019;10:146-154 (In Russ.).
  8. Koroleva O.A., Kogoniya L.M., Byakhova M.M., Titov A.G. Chemotherapy in Elderly Patients with Stomach Cancer. Zlokachestvennyye Opuholi = Malignant Tumoursis. 2018;8;2:64-75 (In Russ.).
  9. Babicheva L.G., Podvyaznikov S.O. Prevention of Neutropenia as an Important Factor in Successful Chemotherapy for Head and Neck Cancer. Opukholi Golovy i Shei = Head and Neck Tumors (HNT). 2021;11;3:72-82 (In Russ.).
  10. Demina E.A., Tumyan G.S., Moiseyeva T.N., Mikhaylova N.B., Myakova N.V., Rumyantsev A.G., et al. Hodgkin Lymphoma. Clinical Recommendations. Sovremennaya Onkologiya = Journal of Modern Oncology. 2020;22;2:6–33 (In Russ.).
  11. Ostroumova O.D., Goloborodova I.V. Drug-Induced Heart Failure (Part 2: Mechanisms of Development, Clinical Signs, Differential Diagnosis, Risk Factors, Treatment and Prevention). Bezopasnost i Risk Farmakoterapii = Safety and Risk of Pharmacotherapy. 2020;8;2:57-65 (In Russ.).
  12. Paramonova O.V., Korenskaya E.G. Treatment of Hypothyroidism in Geriatric Practice. Klinicheskaya Gerontologiya = Clinical Gerontology. 2019;25;5−6:52−59 (In Russ.).
  13. Shnayder N.A., Khasanova A.K., Nasyrova R.F. First Phase of Antipsychotic Metabolism in the Liver: the Role of Oxidation. Farmakogenetika i Farmakogenomika = Pharmacogenetics and Pharmacogenomics. 2022;1:15-30 (In Russ.).
  14. Wong J.D., Bajcar J.M., Wong G.G., Alibhai S.M.H., Huh J.H., Cesta A., et al. Medication Reconciliation at Hospital Discharge: Evaluating Discrepancie. Ann. Pharmacother. 2008;42;10:1373–1379.
  15. Dmitriyeva N.V., Aginova V.V., Petukhova I.N., Grigoryevskaya Z.V., Bagirova N.S. Automation of the Microbiological Laboratory Is a Way to Reduce the Mortality Rate of Cancer Patients. Zlokachestvennyye Opuholi = Malignant Tumoursis. 2020;10;3s1:49–53 (In Russ.).
  16. Elsawy B., Higgins K.E. Geriatric Assessment. American Family Physician. 2011;83;1:48-56.
  17. Penzin O.V., Shvyrev S.L., Zarubina T.V. Results of Implementation in the Clinical Practice the Prognostic Model for Assessing the Risk Development of Mielotoxic Complications of Chemotherapy. Vestnik Novykh Meditsinskikh Tekhnologiy = Journal of New Medical Technologies. 2019;26;1:112-118 (In Russ.).
  18. Ostapenko V.S., Absalyamov R.I. At the Turn of Geriatrics and Oncology: State of the Problem. Rossiyskiy Zhurnal Geriatricheskoy Meditsiny = Russian Journal of Geriatric Medicine. 2023; 2(14): 86–91. (In Russ.).
  19. Van Walree I.C., Scheepers E., Van Huis-Tanja L., et al. A Systematic Review on the Association of the G8 with Geriatric Assessment, Prognosis and Course of Treatment in Older Patients with Cancer. J. Geriatr Oncol. 2019;10:847-858.
  20. Alekseyeva Yu.V., Semiglazova T.Yu., Sharashenidze S.M., Tkachenko E.V., Kasparov B.S., Brish N.A., et al. Assessment and Correction of the Geriatric Status of Patients with Metastatic Colorectal Cancer Against the Background of 1st Line of Systemic Therapy. Sovremennaya Onkologiya = Journal of Modern Oncology. 2021;23;1:133–140 (In Russ.).
  21. Savchenko I.V., Breder V.V., Stilidi I.S., Laktionov K.K., Kudashkin N.E., Egorova A.V., et al. Second Line Drug Therapy for Biliary Cancer. Meditsinskiy Sovet = Medical Council. 2022;22:136-147 (In Russ.).
  22. Stanoyevich U.S., Gorelik S.G., Zvyagin I.N., Polyanskiy M.B., Rukavishnikov A.S. Prevalence of Colorectal Cancer in Older Age Patients. Sovremennyye Problemy Zdravookhraneniya i Meditsinskoy Statistiki = Current Problems of Health Care and Medical Statistics. 2021;4:235–250 (In Russ.).
  23. Sekacheva M.I., Nuriyev R.I., Rozhkov A.A., Semenkov A.V., Bagmet N.N., Boroda A.M. Modern Perspectives in Sequential Therapy for Metastatic Colorectal Cancer with Reference to the Use of Regorafenib. Sovremennaya Onkologiya = Journal of Modern Oncology. 2020;22;3:109-113 (In Russ.).
  24. Besova N.S., Titova T.A., Kalinin A.E., Shalenkov V.A., Stilidi I.S. Case Report of Partial Response on Second Line with Ramucirumab and FOLFIRI in Treatment of 74 Year Old Male with Metastatic HER2-Negative Gastric Adenocarcinoma. Meditsinskiy Sovet = Medical Council. 2021;9:130–136 (In Russ.).
  25. Alekseyeva Yu. V., Semiglazova T.Yu., SHarashenidze S.M., Mgar E.A., Tkachenko E.V., Kondratyev S.V., et al. Application of an Adapted Geriatric Questionnaire to Select Treatment Tactics for Patients with Metastatic Colorectal Cancer. Voprosy Onkologii = Problems in Oncology. 2022;68;S3:27-29 (In Russ.).
  26. Moiseyenko V. M., Moiseyenko F.V., Volkov N.M., Yanus G.A., Kuligina E.Sh., Sokolenko A.P., et al. Prospective II Phase Study on the Evaluation of the Efficacy of Monotherapy with Cetuximab as the First-Line Treatment for Patients with Metastatic Colorectal Cancer with Wild-Type KRas, NRas, and BRAF Genes. Farmateka = Farmateka. 2018;7:82-88 (In Russ.).
  27. García-Alfonso P., Díaz-Rubio E., Abad A., Carrato A., Massutí B., Ortiz-Morales MJ., et al. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis. Drugs Aging. 2021;38;3:219-231.
  28. Metges J.P., Douillard J.Y., Ramée J.F., Dupuis O., Senellart H., Porneuf M., et al. Efficacy and Safety of Panitumumab in a Cohort of Patients with Metastaticcolorectal Cancer in France: PANI OUEST, a Post-EMA Approval Descriptive Study with a Geriatric Oncology Focus. Turk. J. Gastroenterol. 2020;31;10:695-705.
  29. Raimondi A., Fucà G., Leone AG., Lonardi S., Antoniotti C., Smiroldo V., et al. Impact of Age and Gender on the Efficacy and Safety of Upfront Therapy with Panitumumab Plus FOLFOX Followed by Panitumumab-Based Maintenance: A Pre-Specified Subgroup Analysis of the Valentino Study. ESMO Open. 2021;6;5:100246.
  30. Sastre J., Massuti B., Pulido G., Guillén-Ponce C., Benavides M., Manzano J.L., et al. First-Line Single-Agent Panitumumab in Frail Elderly Patients with Wild-Type KRAS Metastatic Colorectal Cancer and Poor Prognostic Factors: A Phase II Study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur. J. Cancer. 2015;51;11:1371-1380.
  31. Idrees M., Tejani M. Current Treatment Strategies for Elderly Patients with Metastatic Colon Cancer. Cureus. 2019;11;5:e4713.
  32. Nevolskikh A.A., Avdeyenko V.A., Belokhvostova A.S., Mikhaleva Yu.Yu., Pochuyev T.P., Zibirov R.F., et al. Neoadjuvant Chemotherapy for Treatment Patients with Rectal Cancer with Adverse Prognostic Factors: A Review. Sovremennaya Onkologiya = Journal of Modern Oncology. 2022;24;3:389–398 (In Russ.).
  33. Khlyamov S.V., Mal G.S., Artyushkova E.B., Gladchenko M.P. Chemotherapy for Oncological Diseases and the Risk of Developing a Cardiotoxic Profile on the Example of the Human Recombined Monoclonal Antibody Bevacizumab. 2023;9;1 (In Russ.).
  34. Rusyaykina Yu.S., Varlamova S.E., Zavyalov A.A. The Effectiveness of Chemotherapy in Elderly Patients, Taking into Account Comorbidity. Ilinskiye Chteniya 2023: Sbornik Materialov Mezhdunarodnoy Nauchno-Prakticheskoy Konferentsii Molodykh Uchenykh i Spetsialistov = Ilyinsky Readings 2023: Collection of Materials from the International Scientific and Practical Conference of Young Scientists and Specialists. Moscow, A.I. Burnazyana FMBC Publ., 2023. P. 95-97 (In Russ.).

 

Conflict of interest. The authors declare no conflict of interest. 
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 28.01.2024. Accepted for publication: 26.02.2024.

© 2025 Scientific journal - "Clinical Bulletin of the FMBС im. A.I. Burnasyan"
Scroll to Top